SCHA vs XBI
Schwab US Small-Cap ETF vs SPDR S&P Biotech ETF
- • SCHA has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • SCHA pays a higher dividend yield (1.05%).
Side-by-side metrics
| Metric | SCHA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.05% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $22.11B | $8.30B |
YTD return | 17.89% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.27 | 1.09 |
P/E ratio | 19.61 | — |
Last price | $33.03 | $133.66 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHA top holdings
| SNDK | SanDisk Corp Ordinary Shares | 3.52% |
| LITE | Lumentum Holdings Inc | 1.37% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 0.62% |
| ATI | ATI Inc | 0.45% |
| CDE | Coeur Mining Inc | 0.40% |
| MKSI | MKS Inc | 0.40% |
| MTSI | MACOM Technology Solutions Holdings Inc | 0.39% |
| NXT | Nextpower Inc Class A | 0.38% |
| SATS | EchoStar Corp Class A | 0.36% |
| MLI | Mueller Industries Inc | 0.33% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SCHA
SCHA (Schwab US Small-Cap ETF) is US small-cap equities. Managed by Schwab, the fund carries $22.1B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.05%. Its largest holding is SanDisk Corp Ordinary Shares (SNDK), which represents 3.5% of the portfolio. Real Estate is the fund's largest sector exposure at 6.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.